Four years of lamivudine treatment in Chinese patients with chronic hepatitis B
Uložené v:
| Názov: | Four years of lamivudine treatment in Chinese patients with chronic hepatitis B |
|---|---|
| Autori: | Chang, T.-T., Lai, C.-L., Chien, R.-N., Guan, R., Lim, S.-G., Lee, C.-M., Ng, K.-Y., Nicholls, G.J., Dent, J.C., Leung, N.W.Y. |
| Prispievatelia: | MEDICINE |
| Zdroj: | Journal of Gastroenterology and Hepatology. 19:1276-1282 |
| Informácie o vydavateľovi: | Wiley, 2004. |
| Rok vydania: | 2004 |
| Predmety: | Asian Continental Ancestry Group, Adult, Male, Hepatitis B virus, Time Factors, Adolescent, Hepatitis B e Antigens - blood, Chronic hepatitis B, 03 medical and health sciences, Viral - blood, Hepatitis B, Chronic, 0302 clinical medicine, Asian People, Humans, Hepatitis B e Antigens, Hepatitis B Antibodies, Hepatitis B Surface Antigens - blood, Lamivudine - therapeutic use, Alanine Transaminase - blood, Chinese, Hepatitis B Surface Antigens, Chronic - blood - drug therapy, Alanine Transaminase, DNA, Hepatitis B Antibodies - blood, Middle Aged, Hepatitis B, Hepatitis B, Chronic - blood - drug therapy, Hepatitis B virus - genetics - immunology, 3. Good health, Treatment Outcome, Lamivudine, DNA, Viral, Reverse Transcriptase Inhibitors, Female, Reverse Transcriptase Inhibitors - therapeutic use, DNA, Viral - blood, Follow-Up Studies |
| Popis: | Background and Aims: This study assessed the efficacy and safety of up to 4 years of lamivudine treatment and the clinical relevance of the emergence of YMDD‐variant hepatitis B virus (HBV).Methods: Fifty‐eight Chinese adult patients with chronic hepatitis B (CHB) were randomized to lamivudine 100 mg/day for up to 5 years and were monitored for YMDD‐variant HBV, hepatitis B e antigen (HBeAg) seroconversion (loss of HBeAg and detectable antibody to HBeAg) and serum alanine aminotransferase (ALT) concentrations. Four‐year data are reported here.Results: The rate of HBeAg seroconversion increased with extended therapy and also with higher baseline ALT concentrations. YMDD‐variant HBV was detected in 67% (39/58) of patients at some point during treatment. After 4 years, a total of 47% (27/58) of patients achieved HBeAg seroconversion. Thirty‐three per cent (13/39) of patients with YMDD‐variant HBV achieved HBeAg seroconversion; this increased to 57% (8/14) in patients with moderately elevated (>2–5 × upper limit of normal) pre‐treatment ALT concentrations. The proportion of patients that achieved normal serum ALT increased from 29% (17/58) at baseline to 69% (31/45) following 4 years of treatment. That included 68% (23/34) of patients with YMDD‐variant HBV and 73% (8/11) of those without the variant. All patients receiving lamivudine had reduced serum concentrations of HBV‐DNA compared with baseline, despite the emergence of YMDD‐variant HBV in 39 patients. Lamivudine was generally well tolerated; there was little change in the number or type of drug‐related adverse events in the fourth year of the study.Conclusions: Despite the emergence of YMDD‐variant HBV, Chinese patients showed increased HBeAg seroconversion and improvement in ALT levels with an increased duration of treatment with lamivudine. |
| Druh dokumentu: | Article |
| Jazyk: | English |
| ISSN: | 1440-1746 0815-9319 |
| DOI: | 10.1111/j.1440-1746.2004.03428.x |
| Prístupová URL adresa: | https://pubmed.ncbi.nlm.nih.gov/15482535 https://europepmc.org/article/MED/15482535 http://ir.lib.ncku.edu.tw/handle/987654321/78135 https://www.ncbi.nlm.nih.gov/pubmed/15482535 https://onlinelibrary.wiley.com/doi/10.1111/j.1440-1746.2004.03428.x/abstract http://hub.hku.hk/handle/10722/76303 https://core.ac.uk/display/37907797 http://hdl.handle.net/10722/76303 |
| Rights: | Wiley Online Library User Agreement |
| Prístupové číslo: | edsair.doi.dedup.....83cdacbfdf9638e3a6a7fd018a8d6a54 |
| Databáza: | OpenAIRE |
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstrakt: | Background and Aims: This study assessed the efficacy and safety of up to 4 years of lamivudine treatment and the clinical relevance of the emergence of YMDD‐variant hepatitis B virus (HBV).Methods: Fifty‐eight Chinese adult patients with chronic hepatitis B (CHB) were randomized to lamivudine 100 mg/day for up to 5 years and were monitored for YMDD‐variant HBV, hepatitis B e antigen (HBeAg) seroconversion (loss of HBeAg and detectable antibody to HBeAg) and serum alanine aminotransferase (ALT) concentrations. Four‐year data are reported here.Results: The rate of HBeAg seroconversion increased with extended therapy and also with higher baseline ALT concentrations. YMDD‐variant HBV was detected in 67% (39/58) of patients at some point during treatment. After 4 years, a total of 47% (27/58) of patients achieved HBeAg seroconversion. Thirty‐three per cent (13/39) of patients with YMDD‐variant HBV achieved HBeAg seroconversion; this increased to 57% (8/14) in patients with moderately elevated (>2–5 × upper limit of normal) pre‐treatment ALT concentrations. The proportion of patients that achieved normal serum ALT increased from 29% (17/58) at baseline to 69% (31/45) following 4 years of treatment. That included 68% (23/34) of patients with YMDD‐variant HBV and 73% (8/11) of those without the variant. All patients receiving lamivudine had reduced serum concentrations of HBV‐DNA compared with baseline, despite the emergence of YMDD‐variant HBV in 39 patients. Lamivudine was generally well tolerated; there was little change in the number or type of drug‐related adverse events in the fourth year of the study.Conclusions: Despite the emergence of YMDD‐variant HBV, Chinese patients showed increased HBeAg seroconversion and improvement in ALT levels with an increased duration of treatment with lamivudine. |
|---|---|
| ISSN: | 14401746 08159319 |
| DOI: | 10.1111/j.1440-1746.2004.03428.x |